BS181

Target: This ligand targets cyclin-dependent kinase 7 (CDK7) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for cyclin-dependent kinase 7 (CDK7). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings cyclin-dependent kinase 7 (CDK7) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Target Degradation: BS181 can be used as a ligand module to construct PROTACs that recruit an E3 ligase and induce ubiquitination-dependent degradation of a chosen target protein. This enables systematic evaluation of degradation potency, selectivity, and ternary complex formation, supporting mechanism-driven optimization of linker length and attachment geometry for improved cellular turnover.

• E3 Ligase Recruitment Optimization: Incorporating BS181 into PROTAC designs allows researchers to probe how ligand orientation and steric properties influence E3 ligase engagement. By varying E3 ligase binders and linker architectures, BS181-based chimeras can be screened to identify conditions that maximize ubiquitin transfer efficiency and sustain target degradation across relevant cellular contexts.

• Ternary Complex Mechanism Studies: BS181-containing PROTACs are suitable for investigating the formation and stability of ternary complexes between the target, E3 ligase, and the chimera. Quantitative binding and degradation correlation studies can clarify whether enhanced degradation arises from improved cooperative binding, altered residence time, or changes in ubiquitination kinetics.

• Proteome-Wide Selectivity Profiling: Using BS181 as a building block, investigators can generate PROTACs to assess how degradation depends on target engagement and off-target recruitment. Proteomics-based workflows can map degradation signatures, distinguish on-target versus collateral effects, and guide refinement toward sharper selectivity through chemical redesign of the BS181 ligand attachment.

• Structure–Activity Relationship Mapping: BS181 can support systematic structure–activity relationship (SAR) studies in PROTAC campaigns by enabling controlled modifications to functional groups and conjugation sites. Measuring degradation potency alongside biochemical binding readouts helps define the ligand features that govern productive ternary complex formation, informing rational design rules for next-generation targeted protein degraders.

BS181 is a CDK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of BS181 is characterized by primary or secondary amine/basic nitrogen centers; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.